Granahan Investment Management LLC Raises Stock Holdings in Taysha Gene Therapies, Inc. $TSHA

Granahan Investment Management LLC grew its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 25.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 883,241 shares of the company’s stock after acquiring an additional 179,270 shares during the quarter. Granahan Investment Management LLC owned about 0.31% of Taysha Gene Therapies worth $3,948,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Marex Group plc purchased a new stake in Taysha Gene Therapies in the 2nd quarter valued at $29,000. E Fund Management Co. Ltd. purchased a new position in Taysha Gene Therapies during the 2nd quarter worth $31,000. Tower Research Capital LLC TRC grew its position in Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after purchasing an additional 10,742 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Taysha Gene Therapies by 143.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after purchasing an additional 4,607 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in Taysha Gene Therapies by 51.9% in the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock valued at $43,000 after purchasing an additional 6,350 shares during the period. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Trading Down 5.3%

NASDAQ TSHA opened at $5.52 on Friday. The company has a quick ratio of 14.04, a current ratio of 14.04 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $1.59 billion, a P/E ratio of -14.53 and a beta of 1.17. Taysha Gene Therapies, Inc. has a 52-week low of $2.53 and a 52-week high of $7.30. The firm has a 50-day moving average price of $5.97 and a 200 day moving average price of $5.36.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Equities research analysts expect that Taysha Gene Therapies, Inc. will post -0.49 EPS for the current year.

Insider Activity at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $6.24, for a total value of $1,248,000.00. Following the sale, the insider directly owned 936,410 shares in the company, valued at $5,843,198.40. The trade was a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TSHA. Canaccord Genuity Group increased their target price on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, April 6th. Robert W. Baird upped their price objective on Taysha Gene Therapies from $12.00 to $15.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a research report on Tuesday, June 23rd. Pivotal Research set a $14.00 target price on Taysha Gene Therapies in a report on Tuesday, June 23rd. Finally, The Goldman Sachs Group upped their price target on Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $12.77.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.